In adenocarcinoma, PD-L1 expression using 22C3 assay at clinically relevant cutoff could be predicted in higher N stage, histologically solid pattern, wild-type EGFR, and ALK positive in lung adenocarcinoma. This evidence concerns the gene EGFR and lung adenocarcinoma.